Microglia

• The Interplay between Cannabinoid Receptors and Microglia in the Pathophysiology of Alzheimer’s Disease (02 Sep 2024)
  
• Research progress on the cannabinoid type-2 receptor and Parkinson’s disease (02 Sep 2024)
  
• Potential of CBD Acting on Cannabinoid Receptors CB1 and CB2 in Ischemic Stroke (02 Sep 2024)
  
• Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders (02 Sep 2024)
  
• Microglial Cannabinoid CB2 Receptors in Pain Modulation (28 Aug 2024)
  
• Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease (27 Aug 2024)
  
• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential (27 Aug 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits (25 Aug 2024)
  
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders (21 Aug 2024)
  
• Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment (20 Aug 2024)
  
• Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases (20 Aug 2024)
  
• Cannabinoid Receptor 2 Alters Social Memory and Microglial Activity in an Age-Dependent Manner (20 Aug 2024)
  
• Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease (19 Aug 2024)
  
• Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders (18 Aug 2024)
  
• Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3 (18 Aug 2024)
  
• CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease (18 Aug 2024)
  
• Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease (18 Aug 2024)
  
• A helping HAND: therapeutic potential of MAGL inhibition against HIV-1-associated neuroinflammation (24 May 2024)
  
• N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA rece (13 May 2024)
  
• Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance (27 Feb 2023)
  
• Quality of Life and a Surveillant Endocannabinoid System (05 Sep 2022)
  
• N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA receptors (01 Sep 2022)
  
• CB2 Receptor in Microglia: The Guardian of Self-Control (01 Sep 2022)
  
• Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression (27 Aug 2022)
  
• Cannabinoids in Chronic Pain: Therapeutic Potential Through Microglia Modulation (13 Aug 2022)
  
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation (05 Aug 2022)
  
• Interaction of Glia Cells with Glioblastoma and Melanoma Cells under the Influence of Phytocannabinoids (05 Aug 2022)
  
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty (31 Jul 2022)